Daiichi Sankyo Company, Limited

$16.53+0.18%(+$0.03)
TickerSpark Score
67/100
Solid
80
Valuation
90
Profitability
55
Growth
80
Health
30
Momentum

Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DSNKY research report →

52-Week Range8% of range
Low $15.56
Current $16.53
High $28.21

Companywww.daiichisankyo.com

Daiichi Sankyo Company, Limited researches and develops, manufactures, imports, markets, and sells pharmaceutical products worldwide. The company offers trastuzumab deruxtecan, an anti-cancer agent and anti-HER2 antibody drug conjugate; mirogabalin for pain treatment; teneligliptin/canagliflozin for type 2 diabetes mellitus treatment; lacosamide anti-epileptic agent; prasugrel, an antiplatelet agent; denosumab for osteoporosis and bone disorders; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine for treating Alzheimer's disease; and laninamivir for anti-influenza treatment. It also provides olmesartan, an antihypertensive agent; levofloxacin, an antibacterial agent; pravastatin for hypercholesterolemia treatment; and loxoprofen, an anti-inflammatory analgesic.

CEO
Hiroyuki Okuzawa
IPO
2008
Employees
18,726
HQ
Tokyo, JP

Price Chart

-35.61% · this period
$27.37$21.46$15.56May 20Nov 18May 20

Valuation

Market Cap
$30.08B
P/E
18.81
P/S
2.28
P/B
2.94
EV/EBITDA
14.72
Div Yield
2.93%

Profitability

Gross Margin
68.49%
Op Margin
9.80%
Net Margin
12.24%
ROE
15.74%
ROIC
6.58%

Growth & Income

Revenue
$2.25T · 19.34%
Net Income
$275.55B · -6.83%
EPS
$148.60 · -4.72%
Op Income
$219.81B
FCF YoY
59.88%

Performance & Tape

52W High
$28.21
52W Low
$15.56
50D MA
$17.52
200D MA
$21.37
Beta
-0.17
Avg Volume
314.31K

Get TickerSpark's AI analysis on DSNKY

Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

30-day money-back guarantee · cancel anytime

Our DSNKY Coverage

We haven't published any research on DSNKY yet

For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.

Generate DSNKY Report →

Similar Companies